NASDAQ:GNMK - GenMark Diagnostics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.75 -0.04 (-0.59 %)
(As of 07/22/2018 05:00 AM ET)
Previous Close$6.75
Today's Range$6.72 - $6.93
52-Week Range$3.63 - $12.55
Volume123,109 shs
Average Volume195,495 shs
Market Capitalization$376.25 million
P/E Ratio-5.58
Dividend YieldN/A
GenMark Diagnostics logoGenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.

Receive GNMK News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments


Debt-to-Equity Ratio0.24
Current Ratio2.79
Quick Ratio2.45


Trailing P/E Ratio-5.58
Forward P/E Ratio-8.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$52.52 million
Price / Sales7.12
Cash FlowN/A
Price / CashN/A
Book Value$1.29 per share
Price / Book5.23


EPS (Most Recent Fiscal Year)($1.21)
Net Income$-61,850,000.00
Net Margins-97.90%
Return on Equity-77.35%
Return on Assets-46.77%


Outstanding Shares55,410,000
Market Cap$376.25

GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions

What is GenMark Diagnostics' stock symbol?

GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."

How were GenMark Diagnostics' earnings last quarter?

GenMark Diagnostics, Inc (NASDAQ:GNMK) issued its quarterly earnings data on Tuesday, May, 1st. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.01. The medical equipment provider had revenue of $20.65 million for the quarter, compared to analysts' expectations of $17.12 million. GenMark Diagnostics had a negative return on equity of 77.35% and a negative net margin of 97.90%. View GenMark Diagnostics' Earnings History.

When is GenMark Diagnostics' next earnings date?

GenMark Diagnostics is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for GenMark Diagnostics.

What price target have analysts set for GNMK?

6 brokerages have issued 1-year price objectives for GenMark Diagnostics' shares. Their forecasts range from $9.00 to $13.00. On average, they expect GenMark Diagnostics' stock price to reach $10.80 in the next year. This suggests a possible upside of 60.0% from the stock's current price. View Analyst Ratings for GenMark Diagnostics.

What is the consensus analysts' recommendation for GenMark Diagnostics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about GenMark Diagnostics stock?

Here are some recent quotes from research analysts about GenMark Diagnostics stock:
  • 1. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (7/18/2018)
  • 2. Needham & Company LLC analysts commented, "On 4/19/18, bioMerieux announced its 1Q18 results, which included 47% FilmArray growth fueled partly by the severe flu season. bioMerieux’s BioFire FilmArray is the market-leading syndromic panel molecular testing system. We estimate that bioMerieux ended 1Q18 with a FilmArray installed base of ~6,750. We believe that bioMerieux’s strong FilmArray growth indicates that the syndromic panel testing market remains significantly under-penetrated and we have increased confidence that GNMK can exceed the 1Q18 revenue consensus when it reports on 5/1/18." (4/24/2018)
  • 3. BTIG Research analysts commented, "The fact that ACOR announced this morning that it will discontinue the tozadenant program (stopping dosing in all currently enrolled studies) came as little surprise following last week’s disclosure of safety issues (our thoughts here). Timing was the only marginal surprise, but based on additional analyses, the company determined that the recently instituted weekly white blood cell count screening may not be adequate to fully ensure the safety of patients. Though this morning’s headline has little incremental impact, it does highlight the added pressure on Inbrija (which is delayed itself following the RTF earlier this year) and formally removes the potential for near- term leverage in the business. Maintain Neutral." (11/20/2017)

Who are some of GenMark Diagnostics' key competitors?

Who are GenMark Diagnostics' key executives?

GenMark Diagnostics' management team includes the folowing people:
  • Mr. Hany Massarany, CEO, Pres & Director (Age 57)
  • Mr. Scott Mendel, Chief Financial Officer (Age 51)
  • Ms. Jennifer Williams, Sr. VP of HR (Age 45)
  • Mr. Michael Gleeson, Sr. VP of North American Commercial Operations (Age 43)
  • Mr. Brian Andrew Mitchell, Sr. VP of Operations (Age 53)

Has GenMark Diagnostics been receiving favorable news coverage?

News headlines about GNMK stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GenMark Diagnostics earned a daily sentiment score of 0.17 on Accern's scale. They also assigned media coverage about the medical equipment provider an impact score of 45.94 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are GenMark Diagnostics' major shareholders?

GenMark Diagnostics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fox Run Management L.L.C. (0.05%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, Jennifer Anne Williams, Jon Faiz Kayyem, Lisa M Giles, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.

Which institutional investors are buying GenMark Diagnostics stock?

GNMK stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have bought GenMark Diagnostics stock in the last two years include Lisa M Giles and Michael Kagnoff. View Insider Buying and Selling for GenMark Diagnostics.

How do I buy shares of GenMark Diagnostics?

Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GenMark Diagnostics' stock price today?

One share of GNMK stock can currently be purchased for approximately $6.75.

How big of a company is GenMark Diagnostics?

GenMark Diagnostics has a market capitalization of $376.25 million and generates $52.52 million in revenue each year. The medical equipment provider earns $-61,850,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. GenMark Diagnostics employs 517 workers across the globe.

How can I contact GenMark Diagnostics?

GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]

MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  326 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  508
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.